Publication:
Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders

Simple item page
dc.contributor.authorKocaman, Gulsen
dc.contributor.authorKahraman, Nese
dc.contributor.authorGurkan Koseoglu, Banu
dc.contributor.authorBilgic, Basar
dc.contributor.authorErtas, Mustafa
dc.contributor.authorGulsen, Yesim
dc.contributor.authorBaykan Baykal, Betul
dc.contributor.institutionauthorMATUR, ZELİHA
dc.date.accessioned2020-10-22T19:39:08Z
dc.date.available2020-10-22T19:39:08Z
dc.date.issued2018-12-01T00:00:00Z
dc.description.abstractIntroduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD.
dc.identifier.citationKocaman G., Kahraman N., Gurkan Koseoglu B., Bilgic B., Matur Z., Ertas M., Gulsen Y., Baykan Baykal B., -Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders-, NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.55, ss.330-336, 2018
dc.identifier.doi10.5152/npa.2017.19257
dc.identifier.pubmed30622389
dc.identifier.scopus85060089435
dc.identifier.trdizinDOI: https://doi.org/10.5152/npa.2017.19257
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24586
dc.identifier.wosWOS:000456607300008
dc.titleEvaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders
dc.typeArticle
dspace.entity.typePublication
local.avesis.idc9afe927-7ac6-4166-96d3-417688104022
local.publication.isinternational1
relation.isAuthorOfPublication3c69fce6-5ba0-4838-9215-eae7a7125446
relation.isAuthorOfPublication.latestForDiscovery3c69fce6-5ba0-4838-9215-eae7a7125446

Files

Collections

Yayınlar - Eserler